McDonald’s Adapts Menu to Meet Needs of GLP-1 Drug Users

McDonald’s is actively reassessing its menu strategy to accommodate an increasing number of customers using GLP-1 medications, which are known for suppressing appetite. In a recent earnings call held on March 6, 2024, executives discussed ongoing efforts to tailor offerings for this growing segment of the market.

CEO Chris Kempczinski emphasized that the adoption of GLP-1 drugs, such as Ozempic and Wegovy, is expected to rise, influencing consumer behavior significantly. He noted, “As adoption grows, we know that consumers’ behavior changes,” highlighting a shift towards a preference for protein-rich foods. This aligns with the trend seen across the food and beverage industry, where companies are adjusting their products to meet the needs of consumers with reduced appetites.

During the call, Vice President Jill McDonald pointed out that McDonald’s already has a selection of high-protein offerings, including Snack Wraps, Sausage Biscuit sandwiches, and Chicken McCrispy Strips. She stated, “We’re also seeing changes around maybe less snacking, changes in some of the beverages that they drink, less sugary drinks.” This observation reflects a broader market trend as consumers on GLP-1 medications tend to prefer smaller portion sizes and healthier options.

The increase in GLP-1 prescriptions in the United States is noteworthy. A report by EY indicated that approximately 10% of the US population is now using some form of GLP-1 medication, reshaping dietary habits and preferences across various demographics. In response, other food brands are also developing products that cater to this new consumer landscape. For instance, Conagra Brands, which owns labels like Slim Jim and Marie Callender’s, is marketing some of its Healthy Choice frozen meals as “GLP-1 Friendly.”

In December 2023, Shake Shack launched its “Good Fit Menu,” featuring high-protein, gluten-free, vegetarian, and “GLP-1-friendly” options. This menu includes burgers wrapped in lettuce instead of buns to cater to health-conscious customers. Such initiatives illustrate a growing recognition across the food industry of the need to adapt to changing consumer demands.

Despite these shifts, McDonald’s reported a robust performance in its latest quarter, achieving a 5.7% increase in global comparable sales, totaling around $7 billion. Following the earnings announcement, the company’s stock price remained stable, reflecting investor confidence in the brand’s ability to navigate evolving market trends.

As McDonald’s continues to explore ways to better serve customers on GLP-1 medications, executives remain optimistic about future innovations and menu adaptations. While specific details on new offerings were not disclosed, the company is committed to understanding and responding to the dietary preferences of this expanding customer base.

This proactive approach not only positions McDonald’s as a leader in the fast-food industry but also aligns with broader trends in health and wellness, showcasing the chain’s adaptability in a rapidly changing market.